HOMEPRODUCTSSERVICESCOMPANYCONTACTFAQResearchDictionaryPharmaMobileSign Up FREE or Login

Bupropion sustained-release for the treatment of dysthymic disorder: an open-label study.

Abstract
Many studies of antidepressants in the treatment of dysthymic disorder (DD) have been conducted, but none has included bupropion sustained-release (SR). The aim of this study was to provide preliminary data on the tolerability and effectiveness of bupropion SR for patients with DD. Twenty-one adult subjects meeting DSM-IV criteria for DD were enrolled in this 8-week open-label study. Bupropion SR was initiated at 150 mg/day and was increased to a maximum of 200 mg, twice daily. Response was defined as a 50% or greater decrease in score on the Hamilton Rating Scale for Depression (HAM-D). Of these 21 subjects, 15 (71.4%) responded to treatment. All paired sample t-tests were highly significant, demonstrating average improvement on all measures of symptomatology and functioning. Subject scores on the HAM-D decreased from 21.7 +/- 5.6 at baseline to 5.9 +/- 3.6 at week 8 (t[19] = 12.74, p < 0.001). The average final dosage was 364 mg/day. None of the subjects dropped out during the trial. Patients with a history of alcohol or chemical abuse were significantly less likely to respond to bupropion. Side effects were reported by eight subjects (38.1%), and the most frequently reported effects were headache, decreased appetite, insomnia, gastrointestinal problems, restlessness, and tremulousness. These findings suggest the effectiveness and high tolerability of bupropion SR for the treatment of DD. Double-blind prospective studies are needed for the comparison of bupropion SR to both placebo and other medications, assessing both initial and sustained responses to treatment.
AuthorsD J Hellerstein, S Batchelder, D Kreditor, M Fedak
JournalJournal of clinical psychopharmacology (J Clin Psychopharmacol) Vol. 21 Issue 3 Pg. 325-9 (Jun 2001) ISSN: 0271-0749 [Print] United States
PMID11386496 (Publication Type: Clinical Trial, Journal Article, Research Support, Non-U.S. Gov't)
Chemical References
  • Antidepressive Agents, Second-Generation
  • Delayed-Action Preparations
  • Bupropion
Topics
  • Adult
  • Antidepressive Agents, Second-Generation (adverse effects, therapeutic use)
  • Brief Psychiatric Rating Scale (statistics & numerical data)
  • Bupropion (adverse effects, therapeutic use)
  • Chi-Square Distribution
  • Delayed-Action Preparations
  • Dysthymic Disorder (drug therapy, psychology)
  • Female
  • Humans
  • Male
  • Middle Aged

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.
Realize the full power of the drug-disease research network!


Choose Username:
Email:
Password:
Verify Password: